Evommune, Inc. (EVMN) - Total Assets
Based on the latest financial reports, Evommune, Inc. (EVMN) holds total assets worth $224.95 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See debt-free asset ratio of Evommune, Inc. to measure how much of total assets are equity-financed.
Evommune, Inc. - Total Assets Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s total assets have evolved over time, based on quarterly financial data. Explore how much of Evommune, Inc.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Evommune, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Evommune, Inc.'s total assets of $224.95 Million consist of 68.2% current assets and 31.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Evommune, Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evommune, Inc.'s current assets represent 68.2% of total assets in 2025, a decrease from 97.3% in 2023.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 35.3% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Evommune, Inc. Competitors by Total Assets
Key competitors of Evommune, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Evommune, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.57 | 2.64 | 2.64 |
| Quick Ratio | 8.57 | 2.64 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $135.57 Million | $46.01 Million | $46.01 Million |
Evommune, Inc. - Advanced Valuation Insights
This section examines the relationship between Evommune, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.16 |
| Latest Market Cap to Assets Ratio | 3.42 |
| Asset Growth Rate (YoY) | 195.8% |
| Total Assets | $224.95 Million |
| Market Capitalization | $769.35 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Evommune, Inc.'s assets at a significant premium (3.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Evommune, Inc.'s assets grew by 195.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evommune, Inc. (2023–2025)
The table below shows the annual total assets of Evommune, Inc. from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $224.95 Million | +195.77% |
| 2024-12-31 | $76.06 Million | -7.53% |
| 2023-12-31 | $82.25 Million | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more